stockrowNeogen Corporation
NEOG Healthcare Medical Devices
Neogen Corporation’s revenue for fiscal 2026 (year ended May 2026) was $870.4 million, down 2.72% from fiscal 2025.
- Revenue
- +6.50%
- EPS
- −129.4%
- Free cash flow
- +135.6%
- Total debt
- −2.31%
Quarter to August 2026, against a year earlier
Follow NEOG
Alert me
Neogen Corporation (NEOG) EPS (diluted)
Neogen Corporation's EPS (diluted) for fiscal 2026 was −$0.04, compared with −$5.03 in fiscal 2025. Over the twelve months to 31 August 2026 it was −$0.25. Over the past ten years it has ranged from −$5.03 (fiscal 2025) to $0.61 (fiscal 2018); the current reading is higher than 33% of that period. Neogen Corporation ranks 49th of 147 Medical Devices companies by EPS (diluted).
EPS (diluted), annual
Embed this chart
Annual newest first
| Period | EPS (diluted) | Change |
|---|---|---|
| FY2026 | −$0.04 | — |
| FY2025 | −$5.03 | — |
| FY2024 | −$0.04 | — |
| FY2023 | −$0.12 | — |
| FY2022 | $0.45 | (21.05%) |
| FY2021 | $0.57 | 0.88% |
| FY2020 | $0.57 | (1.74%) |
| FY2019 | $0.58 | (4.96%) |
| FY2018 | $0.61 | 41.52% |
| FY2017 | $0.43 | 17.51% |
Quarterly newest first
| Period | EPS (diluted) | Change |
|---|---|---|
| Aug 2026 | −$0.05 | — |
| May 2026 | −$0.05 | — |
| Feb 2026 | −$0.08 | — |
| Nov 2025 | −$0.07 | — |
| 43 more quarters | Free account |
Against its own ten years
EPS (diluted) against peers
| Company | EPS (diluted) |
|---|---|
| UFPT UFP Technologies, Inc. compare | $9.81 |
| TMDX TransMedics Group, Inc. compare | $3.69 |
| INSP Inspire Medical Systems, Inc. compare | $3.44 |
| ITGR Integer Holdings Corporation compare | $2.98 |
| BFLY Butterfly Network, Inc. compare | −$0.21 |
| NEOG Neogen Corporation | −$0.25 |
| AXGN AxoGen, Inc. compare | −$0.65 |
| ESTA Establishment Labs Holdings Inc. compare | −$1.31 |
| ALMR Alamar Biosciences, Inc. compare | −$2.77 |
What EPS (diluted) is
Diluted EPS tells an investor how much profit a company earned for each share, counting the extra shares that options and convertible securities could create.
Reported line item
More on NEOG
- Revenue
- Net income
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement